Nuclear Export Inhibitor, Selinexor+Bortezomib+Dexamethasone (SVd), Phase 3, Bortezomib+Dexamethasone (Vd), Relapsed Refractory Multiple Myeloma (RRMM), 1,2,3 prior line of therapy
### Instruction:
Identify the study with the following condition. 
### Input:
Nuclear Export Inhibitor, Selinexor+Bortezomib+Dexamethasone (SVd), Phase 3, Bortezomib+Dexamethasone (Vd), Relapsed Refractory Multiple Myeloma (RRMM), 1,2,3 prior line of therapy 
### Output:
Popular Name is BOSTON, Study ID is NCT03110562